TRC105 for Recurrent Glioblastoma
NCT01778530 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it was terminated. It studies TRC105 in Glioblastoma Multiforme. The registry lists an enrollment of 2 participants at 1 site in 1 country. The registry lists a start date of 31 Dec 2012 and a primary completion date of 28 Feb 2014.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01778530 |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | National Cancer Institute (NCI) |
| Enrollment | 2 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Glioblastoma Multiforme |
| Drugs | TRC105 |
| Start | 31 Dec 2012 |
| Primary completion | 28 Feb 2014 |
| Study completion | 28 Feb 2014 |
| Last update posted | 7 Oct 2015 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Joohee Sul, M.D.
National Cancer Institute (NCI)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01778530
Each answer restates registry values shown on this page.
What is NCT01778530?
NCT01778530 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies TRC105 in Glioblastoma Multiforme.
Who leads NCT01778530?
The registry names Joohee Sul, M.D. (principal investigator, National Cancer Institute (NCI)) as the overall official.
Where does NCT01778530 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01778530 study?
The registered drug and biological interventions are TRC105.
When did NCT01778530 end?
The registry lists a primary completion date of 28 Feb 2014 and a study completion date of 28 Feb 2014. The sponsor last updated the record on 7 Oct 2015.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.